Middle East And Africa Prophylaxis Of Organ Rejection Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2022 –2029 |
 Размер рынка (базовый год) |
USD 59.81 Million |
 Размер рынка (прогнозируемый год) |
USD 69.23 Million |
 CAGR |
% |
| Основные игроки рынка |
>Рынок профилактики отторжения органов на Ближнем Востоке и в Африке по причине (эпидемиологическое воздействие, антибактериальная профилактика, профилактика против других патогенов и др.), лечению (амбулаторные иммунодепрессанты, стационарные иммунодепрессанты и др.), способу введения (перорально, внутривенно), органу (почка, печень, сердце, легкое и др.), типу пациента (детский, взрослый), конечному пользователю (больницы, клиники, домашняя медицинская помощь и др.), каналу сбыта (прямой тендер, аптеки и др.), стране (Саудовская Аравия, Южная Африка, Израиль, Кувейт, ОАЭ и остальные страны Ближнего Востока и Африки), тенденциям рынка и прогнозу до 2029 г.
Анализ рынка и идеи: рынок профилактики отторжения органов на Ближнем Востоке и в Африке
Ожидается, что рынок профилактики отторжения органов на Ближнем Востоке и в Африке будет расти в прогнозируемый период с 2022 по 2029 год. По данным Data Bridge Market Research, рынок растет со среднегодовым темпом роста 2,0% в прогнозируемый период с 2022 по 2029 год и, как ожидается, достигнет 69,23 млн долларов США к 2029 году по сравнению с 59,81 млн долларов США в 2021 году. Рост распространенности трансплантации органов и более широкое использование иммунодепрессантов, вероятно, станут основными факторами, которые будут стимулировать спрос на рынке в прогнозируемый период.
Термин профилактика означает лечение или действие, предпринятое для предотвращения заболевания. Профилактика отторжения органов относится к профилактике отторжения органов с помощью лекарств. Пациенты, перенесшие трансплантацию, должны поддерживаться на режиме иммуносупрессии для профилактики отторжения, чтобы помочь обеспечить выживаемость трансплантата. Отторжение трансплантата - это процесс, в котором иммунитет реципиента трансплантата в настоящее время профилактика отторжения реализуется с использованием ингибиторов кальциневрина, ингибиторов mTOR, антиметаболитов и кортикостероидов. Лечебные средства улучшают краткосрочные последствия трансплантации органов, но определенные улучшения. Пациенты-реципиенты, перенесшие трансплантацию солидных органов, должны принимать лекарства против отторжения. Это связано с тем, что иммунная система разрушит пересаженный орган.
Факторами, обусловливающими рост рынка профилактики отторжения органов на Ближнем Востоке и в Африке, являются возросшая распространенность трансплантации органов, рост хирургических процедур, рост популяции реципиентов и запуски продуктов. Однако факторами, которые, как ожидается, будут сдерживать рынок, являются рост стоимости процедуры трансплантации, неосведомленность о трансплантации органов и риски, связанные с получением пациентом пересаженного органа.
- On the other hand, strategic initiatives by market players, rise in research and developments and use of immunosuppressant may act as an opportunity for the growth of the Middle East and Africa prophylaxis of organ rejection market. The need for skilled expertise and the regulatory approval may create challenges for the Middle East and Africa prophylaxis of organ rejection market. There are recent developments related to the Middle East and Africa prophylaxis of organ rejection market. The Middle East and Africa prophylaxis of organ rejection market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Prophylaxis of Organ Rejection Market Scope and Market Size
Middle East and Africa prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel.
- On the basis of cause, the Middle East and Africa prophylaxis of organ rejection market is segmented into epidemiologic exposure, antibacterial prophylaxis, prophylaxis against other pathogens and others. In 2022, the epidemiologic exposure segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market due to availability of direct information and presence of pathogens related to prophylaxis of organ rejection in U.A.E
- On the basis of treatment, the Middle East and Africa prophylaxis of organ rejection market is segmented into outpatient immunosuppressant, inpatient immunosuppressant and others. In 2022, the outpatient immunosuppressant segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market, since it can achieve the sustained and specific immune response against damaged cells and availability of cyclosporine.
- On the basis of route of administration, the Middle East and Africa prophylaxis of organ rejection market is segmented into oral and intravenous. In 2022, the oral segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection due to increased availability and intake of oral tablets and capsules.
- On the basis of organ, the Middle East and Africa prophylaxis of organ rejection market is segmented into kidney, liver, heart, lung and others. In 2022, the kidney segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection due to increased incidence of kidney failure and presence of reimbursement policies such as Medicare, for the recipient’s insurance.
- On the basis of patient type, the Middle East and Africa prophylaxis of organ rejection market is segmented into pediatric and adults. In 2022, the adults segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market, due to increased prevalence of chronic diseases and genetic conditions of the adult patients, weak immune system in adults and waiting list of adult recipients more than the waiting list of children and women.
- On the basis of end user, the Middle East and Africa prophylaxis of organ rejection market is segmented into hospitals, clinics, home healthcare and others. In 2022, the hospitals segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market due to rise in medical care and collaboration with other hospitals in Middle East and Africa for delivery of the donor organs to the recipient patients are predicted to dominate the market.
- On the basis of distribution channel, the Middle East and Africa prophylaxis of organ rejection market is segmented into direct tenders, pharmacy stores and others. In 2022, the direct tenders segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market due to surge in demand of outpatient immunosuppressant by pharmaceutical companies and guaranteed payment, are predicted to dominate the market
Middle East and Africa Prophylaxis of Organ Rejection Market Country Level Analysis
Middle East and Africa prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel.
The countries covered in the Middle-East and Africa Prophylaxis of Organ Rejection market report are the South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa.
Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2029 as Middle East and Africa counties are major developing countries and focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services. South Africa is expected to dominate in the market in the Middle East and Africa market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Потенциал роста профилактики отторжения органов в странах с развивающейся экономикой и стратегические инициативы участников рынка создают новые возможности на рынке профилактики отторжения органов в чистых помещениях на Ближнем Востоке и в Африке .
Профилактика отторжения органов на Ближнем Востоке и в Африке также предоставляет вам подробный анализ рынка для роста каждой страны в определенной отрасли с продажами счетчиков частиц для чистых помещений, влиянием прогресса в отторжении органов в нормативных сценариях с их поддержкой рынка профилактики отторжения органов на Ближнем Востоке и в Африке. Данные доступны за исторический период с 2020 по 2021 год.
Конкурентная среда и рынок профилактики отторжения органов на Ближнем Востоке и в Африке: анализ акций
Конкурентная среда профилактики отторжения органов на Ближнем Востоке и в Африке содержит подробную информацию по конкурентам. Включены следующие сведения: обзор компании, финансовые показатели компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, испытания продуктов, одобрения продуктов, патенты, ширина и дыхание продукта, доминирование приложений, кривая жизненной линии технологий. Приведенные выше данные относятся только к фокусу компании, связанному с рынком счетчиков частиц для чистых помещений.
Основными компаниями, обеспечивающими профилактику отторжения органов на Ближнем Востоке и в Африке, являются Panacea Biotec, WOCKHARDT, Accord-UK Ltd, Veloxis Pharmaceuticals, Inc, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy's Laboratories, Ltd, Viatris Inc, Glenmark, Biocon, Pfizer Inc, Mayne Pharma Group Limited, Hikma Pharmaceuticals PLC, AbbVie Inc., Apotex Inc, Zydus Pharmaceuticals, Inc и CSL Behring и другие.
Стратегические инициативы участников рынка наряду с новыми технологическими достижениями в области профилактики отторжения органов заполняют пробел в области трансплантации органов.
Например,
- В ноябре 2020 года Concord Biotech и Lupin получили одобрение FDA США на дженерики иммунодепрессантов в капсулах. Полученное одобрение увеличит продажи иммунодепрессантов в капсулах, используемых при отторжении органов.
Сотрудничество, совместные предприятия и другие стратегии участников рынка расширяют рынок компании на Ближнем Востоке и в Африке в области профилактики отторжения органов, что также дает организациям возможность улучшить свое предложение лечебных средств.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 BY CAUSE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: EPIDEMIOLOGY SNAPSHOT
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF ORGAN TRANSPLANTATIONS
5.1.2 RISE IN CHRONIC DISEASES
5.1.3 RISE IN CLINICAL TRIALS
5.1.4 RISE IN RECIPIENT PATIENTS
5.1.5 PRODUCT APPROVALS
5.2 RESTRAINTS
5.2.1 RISE IN COST OF TRANSPLANTATION PROCEDURE
5.2.2 LACK OF AWARENESS ABOUT ORGAN TRANSPLANTATION
5.2.3 RISKS INCLUDED WITH THE PATIENT RECEIVES TRANSPLANTED ORGAN
5.2.4 ETHICAL ISSUES RELATED TO ORGAN TRANSPLANTATION
5.3 OPPORTUNITIES
5.3.1 RISE IN RESEARCH AND DEVELOPMENTS
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
5.3.3 RISE IN USE OF IMMUNOSUPPRESSANT
5.4 CHALLENGES
5.4.1 SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE USE OF PROPHYLAXIS OF ORGAN REJECTION
5.4.2 STRINGENT REGULATIONS
6 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE
6.1 OVERVIEW
6.2 EPIDEMIOLOGIC EXPOSURE
6.2.1 HOSPITAL EXPOSURE
6.2.2 COMMUNITY EXPOSURE
6.3 ANTIBACTERIAL PROPHYLAXIS
6.3.1 POST-TRANSPLANT PROPHYLAXIS
6.3.2 PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS
6.4 PROPHYLAXIS AGAINST OTHER PATHOGENS
6.5 OTHERS
7 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 OUTPATIENT IMMUNOSUPPRESSANT
7.2.1 CALCINEURIN INHIBITORS
7.2.1.1 CYCLOSPORINE
7.2.1.2 TACROLIMUS
7.2.1.2.1 IMMEDIATE RELEASE
7.2.1.2.2 EXTENDED RELEASE
7.2.2 CORTICOSTEROIDS
7.2.2.1 METHYLPREDNISOLONE
7.2.2.2 PREDNISONE
7.2.2.3 OTHERS
7.2.3 MYCOPHENOLIC ACIDS
7.2.3.1 MYCOPHENOLATE MOFETIL
7.2.3.2 MYCOPHENOLATE SODIUM
7.2.4 MTOR INHIBITORS
7.2.4.1 SIROLIMUS
7.2.4.2 EVEROLIMUS
7.2.5 AZATHIOPRINE
7.2.6 OTHERS
7.3 INPATIENT IMMUNOSUPPRESSANT
7.3.1 BELATACEPT
7.3.2 BASILIXIMAB
7.3.3 OTHERS
7.4 OTHERS
7.4.1 ERYTHROPOIESIS-STIMULATING AGENTS
7.4.1.1 ERYTHROPOIETIN
7.4.1.2 DARBEPOETIN
7.4.2 ANTI-VIRAL AGENTS
7.4.2.1 VALGANCICLOVIR
7.4.2.2 LAMIVUDINE
7.4.2.3 ADEFOVIR
7.4.2.4 OTHERS
7.4.3 OTHERS
8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.2.1 TABLET
8.2.1.1 IMMEDIATE RELEASE
8.2.1.2 EXTENDED-RELEASE
8.2.2 ORAL SOLUTION
8.2.3 OTHERS
8.3 INTRAVENOUS
9 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN
9.1 OVERVIEW
9.2 KIDNEY
9.3 LIVER
9.4 HEART
9.5 LUNG
9.6 OTHERS
10 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 PEDIATRIC
11 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 HOME HEALTHCARE
11.5 OTHERS
12 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 PHARMACY STORES
12.3.1 HOSPITAL PHARMACY
12.3.2 RETAIL PHARMACY
12.3.3 ONLINE PHARMACY
12.4 OTHERS
13 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 ISRAEL
13.1.4 KUWAIT
13.1.5 U.A.E
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 QUESTIONNAIRE
16 RELATED REPORTS
Список таблиц
TABLE 1 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 72 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 73 SAUDI ARABIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 74 SAUDI ARABIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 75 SAUDI ARABIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 76 SAUDI ARABIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 SAUDI ARABIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 78 SAUDI ARABIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 79 SAUDI ARABIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 SAUDI ARABIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 81 SAUDI ARABIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 82 SAUDI ARABIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 83 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 84 SAUDI ARABIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 85 SAUDI ARABIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 86 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 87 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 88 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 89 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 90 SAUDI ARABIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 92 SOUTH AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 93 SOUTH AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 94 SOUTH AFRICAPROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 95 SOUTH AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 96 SOUTH AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 97 SOUTH AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 98 SOUTH AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 99 SOUTH AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 100 SOUTH AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 SOUTH AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 102 SOUTH AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 103 SOUTH AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 104 SOUTH AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 105 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 SOUTH AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 SOUTH AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 108 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 109 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 111 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 112 SOUTH AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 113 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 117 ISRAEL OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 118 ISRAEL CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 119 ISRAEL TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 120 ISRAEL MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 121 ISRAEL MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 122 ISRAEL CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 123 ISRAEL INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 124 ISRAEL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 125 ISRAEL ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 126 ISRAEL ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 127 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 ISRAEL ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 129 ISRAEL TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 130 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 131 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 132 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 133 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 134 ISRAEL PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 136 KUWAIT EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 137 KUWAIT ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 138 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 139 KUWAIT OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 140 KUWAIT CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 141 KUWAIT TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 142 KUWAIT MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 143 KUWAIT MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 144 KUWAIT CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 145 KUWAIT INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 146 KUWAIT OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 147 KUWAIT ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 148 KUWAIT ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 149 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 150 KUWAIT ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 151 KUWAIT TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 152 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 153 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 154 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 KUWAIT PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 157 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 158 U.A.E EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 159 U.A.E ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 160 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 161 U.A.E OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 162 U.A.E CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 163 U.A.E TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 164 U.A.E MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 165 U.A.E MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 166 U.A.E CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 167 U.A.E INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 168 U.A.E OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 169 U.A.E ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 170 U.A.E ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 171 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 172 U.A.E ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 173 U.A.E TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 174 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 175 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 176 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 178 U.A.E PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 179 REST OF MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
Список рисунков
FIGURE 1 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DBMR POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED PREVALENCE OF ORGAN TRANSPLANTATION, RISE IN RECIPIENT PATIENTS, AND PRODUCT APPPROVALS ARE EXPECTED TO DRIVE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 TO 2029
FIGURE 13 EPIDEMIOLOGIC EXPOSURE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 & 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PROPHYLAXIS OF ORGAN REJECTION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE, 2021
FIGURE 16 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE REGIONAL LEVEL, 2021
FIGURE 17 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: PREVALENCE (2018-2021) AT REGIONAL LEVEL SNAPSHOT
FIGURE 18 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: SURVIVAL OF PATIENT SNAPSHOT
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET
FIGURE 20 INCREASE COUNT OF KIDNEY TRANSPLANTATIONS IN THE U.S., 2020
FIGURE 21 TOTAL NUMBER OF ORGAN TRANSPLANTATION IN THE MIDDLE EAST & AFRICA SCENARIO, 2020
FIGURE 22 TOTAL NUMBER OF PATIENTS ON WAITING LIST VS TRANSPLANTS PERFORMED BY ORGAN IN 2020
FIGURE 23 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2021
FIGURE 24 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2021
FIGURE 28 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2021
FIGURE 36 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2020-2029 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2021
FIGURE 40 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2020-2029 (USD MILLION)
FIGURE 41 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 42 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2021
FIGURE 44 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 45 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 46 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 48 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 49 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 50 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SNAPSHOT (2021)
FIGURE 52 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021)
FIGURE 53 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 54 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 55 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE (2022-2029)
FIGURE 56 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY SHARE 2021 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
